Cargando…

CRPC Membrane-Camouflaged, Biomimetic Nanosystem for Overcoming Castration-Resistant Prostate Cancer by Cellular Vehicle-Aided Tumor Targeting

Castration-resistant prostate cancer (CRPC) is the most common malignant tumor of the male urinary system. Nanodrug delivery systems (NDDS) have been widely applied in drug delivery for tumor therapy; however, nanotherapeutics encounter various biological barriers that prevent successful accumulatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Kai, Li, Zheng, Hu, Qiang, Sun, Jianfei, Chen, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998744/ https://www.ncbi.nlm.nih.gov/pubmed/35408983 http://dx.doi.org/10.3390/ijms23073623

Ejemplares similares

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
por: Li, Yan, et al.
Publicado: (2022)

Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC)
por: Humphreys, Michael R, et al.
Publicado: (2013)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Henríquez, Iván, et al.
Publicado: (2021)

Cell membrane camouflaged biomimetic nanoparticles: Focusing on tumor theranostics
por: Zhu, Li, et al.
Publicado: (2022)

Biomimetic Nanoparticles Camouflaged in Cancer Cell Membranes and Their Applications in Cancer Theranostics
por: Jin, Jiefu, et al.
Publicado: (2020)

Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application
por: Yan, Jingjing, et al.
Publicado: (2022)

Membrane-camouflaged biomimetic nanoparticles as potential immunomodulatory solutions for sepsis: An overview
por: Wang, Yanbei, et al.
Publicado: (2023)

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Gamat-Huber, Melissa, et al.
Publicado: (2020)

Cell Membrane-Camouflaged Nanoparticles: A Promising Biomimetic Strategy for Cancer Theragnostics
por: Vijayan, Veena, et al.
Publicado: (2018)

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
por: Kawahara, Takashi, et al.
Publicado: (2012)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Biomimetic inorganic camouflage circumvents antibody-dependent enhancement of infection
por: Wang, Xiaoyu, et al.
Publicado: (2017)

Cell membrane camouflaged nanoparticles: a new biomimetic platform for cancer photothermal therapy
por: Wu, Minliang, et al.
Publicado: (2019)

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
por: Teo, Min Yuen, et al.
Publicado: (2018)

Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review
por: Tresnanda, Raden Indra, et al.
Publicado: (2021)

Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients
por: Nishimura, Kazuo, et al.
Publicado: (2022)

Inflammation and Microbiota Regulation Potentiate Pneumonia Therapy by Biomimetic Bacteria and Macrophage Membrane Nanosystem
por: Li, Yuan, et al.
Publicado: (2023)

Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions
por: Scott, Rodney J., et al.
Publicado: (2021)

ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
por: Choi, Jae Duck, et al.
Publicado: (2021)

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of (225)Ac-PSMA (Prostate-Specific Membrane Antigen)
por: Belli, Maria Luisa, et al.
Publicado: (2020)

Nanosystems as Vehicles for the Delivery of Antimicrobial Peptides (AMPs)
por: Martin-Serrano, Ángela, et al.
Publicado: (2019)

SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer
por: Chen, Jiyuan, et al.
Publicado: (2020)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
por: Tan, Pui S, et al.
Publicado: (2014)

Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)
por: Bremmer, Felix, et al.
Publicado: (2014)

Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients
por: Lo, Ernest N., et al.
Publicado: (2015)

DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)
por: Rathi, Nityam, et al.
Publicado: (2018)

An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
por: Meier, Richard, et al.
Publicado: (2016)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
por: Delanoy, Nicolas, et al.
Publicado: (2021)

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Pachynski, Russell K, et al.
Publicado: (2021)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
por: Lozano, Rebeca, et al.
Publicado: (2021)

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
por: McNeel, Douglas G, et al.
Publicado: (2022)

Biomimetic platelet-camouflaged drug-loaded polypyrrole for the precise targeted antithrombotic therapy
por: Zhao, Zhining, et al.
Publicado: (2023)

Down-regulation of RB1 and TP53 as potential predicting biomarkers for castration-resistant prostate cancer (CRPC): Indonesian retrospective cohort study
por: Soerohardjo, Indrawarman, et al.
Publicado: (2020)

The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with (223)Ra: first in human study
por: Sciuto, Rosa, et al.
Publicado: (2021)

Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy
por: Hoshi, Senji, et al.
Publicado: (2022)

Lipid-Based Nanosystems as a Tool to Overcome Skin Barrier
por: Sguizzato, Maddalena, et al.
Publicado: (2021)

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
por: Wargowski, Ellen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_grlahqffc5sbnn9bjamsj1drbi